Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease, which causes progressive deformity and destruction of the joints, thus leading to disability and even premature death. The condition is characterized by the aggressive infiltration of the synovial lining of the joints by both monocytes and T lymphocytes, together with proliferation of fibroblastic lining cells. This hyperproliferative pannus invades and subsequently destroys the underlying cartilage and bone. Synovial expansion is dependent on an adequate blood supply for nutrients and oxygen. However, with time, the increased proliferative activity of the pannus will outstrip the capacity of existing blood vessels for delivery of oxygen, nutrients and inflammatory cells to the lesion. The need for new blood vessel formation or angiogenesis, therefore, becomes critically important.
There is mounting evidence that vascular endothelial growth factor (VEGF), a potent endothelial cell mitogen and vascular permeability factor, may play a pivotal role in RA. Within the synovial environment, resident macrophages and fibroblast-like synovial cells have been found to express VEGF protein, while mRNA encoding for both VEGF receptors (Flt-1 and KDR) has been detected on microvascular endothelial cells. [1] [2] [3] [4] [5] [6] Elevated levels of VEGF have been detected in the synovial fluid and serum from RA patients when compared to healthy controls, and serum VEGF levels have been shown to correlate with disease severity. 1, 2, 7 Following successful therapy of RA with monoclonal anti-TNFa antibody, a study from our group demonstrated significant but incomplete reduction of serum VEGF levels. 2 More recently, we have shown that serum VEGF levels at presentation with early RA correlate significantly with development of radiographic damage after 1 year. 7 Furthermore, we observed that expression of VEGF in RA synovial membrane cultures in vitro was upregulated by hypoxia and inflammatory cytokines (TNFa and IL-1), suggesting that there is both a hypoxic and an inflammatory trigger for VEGF expression. 2 In conjunction with these clinical observations, we utilized an experimental model, collagen-induced arthritis (CIA) in DBA/1 mice, to study the role of VEGF in arthritis. Using this model, we showed that synovial cells isolated from arthritic mice produced significantly higher levels of VEGF in vitro when compared to shamimmunized mice or healthy controls, with the amount of VEGF released correlating with the severity of arthritis and with the extent of paw swelling. 8 Intervention using a soluble form of the Flt-1 VEGF receptor (sFlt-1), which was polyethylene glycol (PEG)-linked to increase its in vivo half-life, partially abrogated disease, as indicated by a reduction in clinical scores and paw swelling relative to untreated mice. Furthermore, histological
analysis was able to demonstrate that mice receiving sFlt-1 treatment exhibited reduced bone and cartilage destruction. 8 Taken together, these data would suggest that VEGF has an important role in RA pathogenesis and is, therefore, a potential target for therapy.
With this background information, we proposed to use an adenoviral delivery system to inhibit VEGF activity in CIA. Adenoviruses have been successfully employed at our Institute to modulate the severity of CIA. For example, adenovirus-mediated gene delivery of a dimeric human p55 TNF receptor-IgG fusion protein ameliorated CIA for up to 10 days after disease onset. 9 Subsequently, adenovirus-mediated transfer of CTLA4Ig and murine IL-10 were also shown to inhibit established disease. 10, 11 In the present study, we utilized adenovirus expressing the secreted form of the extracellular domain of the Flt-1 VEGF receptor, which has previously been demonstrated to suppress tumour growth and vascularization in mice. 12 We hypothesized that administration of adenovirus expressing sFlt-1 in the CIA model by the intravenous route would allow longterm expression of sFlt-1, and permit us to decipher whether targeting neovascularization in CIA would modify the disease.
Our data demonstrate that adenoviral delivery of sFlt-1 significantly suppressed disease activity in CIA, particularly paw swelling. This was observed despite induction of antiadenoviral antibodies in the mice. Furthermore, specific blockade of VEGF activity resulted in reduced joint levels of the vascular marker von Willebrand factor, indicating that VEGF blockade was associated with reduced synovial vascular density. These observations support the concept that blockade of VEGF activity might be of therapeutic benefit in RA.
Methods

Recombinant adenoviral vectors
The replication-deficient adenovirus vectors used in this study were partially E1a-, E1b-and E3-deleted vectors based on human adenovirus type 5. 13, 14 Each vector contained an expression cassette with a cytomegalovirus promoter/enhancer, pUC 19 polylinker, SV40 splice and poly (A) tail sequence. The adenovirus encoding for human soluble VEGF receptor 1 (AdvsFlt-1) was a kind gift from Professor Ron Crystal (Cornell University New York, NY, USA). The gene product is 1-657 amino acids of the full receptor with the unique 31 amino-acid C-terminal. The cDNA encodes for six of the seven extracellular Ig-like domains, but lacks the transmembrane and intracellular regions. 12 Adenovirus containing no insert (Adv0) was kindly donated by Dr M. Wood (University of Oxford, UK).
Viruses were propagated in 293 human embryonic kidney carcinoma cell line (HEK 293; ATCC, USA), and were routinely cultured in DMEM (BioWhittaker, Verviers, Belgium) containing 5% foetal calf serum (FCS; Flow Technologies, Irvine, UK), 2 mM L-glutamine and 100 U/ml penicillin/streptomycin in 5% CO 2 at 371C. Virus was released by at least three freeze/thaw cycles, and then purified by two rounds of caesium chloride (Boehringer Mannheim, Lewes, East Sussex, UK) density gradient centrifugation. Banded virus was recovered, spin dialysed over Sepharose CL6B (Pharmacia, Uppsala, Sweden), filtered and stored at À801C in 10% glycerol (BDH Chemicals, Poole, UK) before use. The final preparation was titred and assessed for its ability to form plaques in HEK 293 cell monolayers. For adenoviral infection, HEK 293 cells were resuspended in 2 ml serum-free RPMI 1640 with either AdvsFlt-1 or Adv0, at multiplicity of infection (m.o.i.) of 100:1, or left uninfected for 2 h. Infection was terminated by incubation in RPMI 1640 medium supplemented with 5% FCS for a further 48 h to allow for overexpression of proteins.
Adenoviral infection of human RA fibroblasts in vitro
Synovial membrane samples, obtained from RA patients undergoing joint replacement, were digested with 5 mg/ ml type IV collagenase (Sigma, Poole, UK) and 150 mg/ ml type I DNAse (Sigma, UK). 15 Tissue was pipetted through a 200 ml nylon mesh, and cells were resuspended in RPMI plus 5% FCS at a concentration of 2 Â 10 6 /ml. Cells were cultured in a total volume of 1 ml/200 mm 2 . Following removal of nonadherent cells, the remaining adherent cells were cultured until a confluent monolayer of fibroblasts was obtained. 16 Fibroblasts were routinely used between the fourth and sixth passage. For adenoviral infection, cells were resuspended in 1 ml serum-free RPMI 1640 with either AdvsFlt-1 or Adv0, at an m.o.i. of between 500:1 and 1000:1, or left uninfected for 8 h. Infection was terminated by incubation in RPMI 1640 medium supplemented with 5% FCS for a further 24 h to allow for overexpression of proteins.
Induction and assessment of arthritis
A single intradermal injection of 100 mg bovine type II collagen, purified in-house from articular cartilage 17 and emulsified in complete Freund's adjuvant (Difco, MI, USA), was used to induce arthritis in male DBA/1 (H-2 q ) mice aged 8-12 weeks (Harlan UK Limited, Oxon, UK). Disease onset was usually 14-40 days after immunization, and was considered to occur on the day that swelling or erythema in the paws was observed. Clinical score, a composite index of disease severity and the number of limbs affected, was assessed daily to monitor disease progression. The scoring used was as follows: 0¼normal; 1¼slight oedema and erythema; 2¼prominent oedema and erythema; 2.5¼extreme oedema and erythema and 3¼joint rigidity. In conjunction with this scoring, paw thickness was measured by microcalipers (Röhm BG Ltd, Kingston-Upon-Thames, UK) as an index of paw swelling and oedema.
Treatment of CIA with adenovirus expressing sFlt-1
Adenovirus expressing sFlt-1 (AdvsFlt-1) was injected intravenously (i.v.) via the tail vein in 100 ml isotonic PBS, with animals receiving adenovirus without insert (Adv0) as controls. Adenoviruses were administered on the day of disease onset (day 1) and the animals were subsequently left untreated until the end of the experiment. A further group of mice was left untreated. Arthritis was monitored daily for 13 days before termination. At the end of the experiments, animals were killed humanely, and hind limbs were processed for histological analysis, as detailed below. Draining inguinal lymph nodes were removed for the isolation of mononuclear cells for in vitro proliferation assays.
In separate experiments, groups of either naïve or arthritic mice were killed 24, 72 h, 7 or 13 days after i.v. . Sample extracts were separated on 10% (w/v) sodium dodecyl sulphate-polyacrylamide gels (SDS-PAGE) at 70 V overnight, before transfer onto polyvinyl difluoride PVDF membranes (Millipore, Watford, UK) at 100 V for a further 90 min. The membranes were blocked with blocking buffer (5% (w/v) Fat-free milk, 0.1% (v/v) Tween 20 in PBS) and then blotted using goat anti-human sFlt-1 (R&D Systems, Abingdon, UK; 1:1000) followed by horseradish peroxidase conjugated rabbit anti-goat antibody (Dako; 1:2000), and visualized by enhanced chemiluminescence using Hyperfilm MP (Amersham Pharmacia Biotech, Little Chafont, UK).
Assessment of antiadenovirus antibodies
Cell lysates from Adv0-or AdvsFlt-1-infected HEK 293 cells (1:250 dilution) or recombinant human sFlt-1 (2.5 mg; R&D Systems, Abingdon, UK) were used to coat microtitre plates in carbonate buffer (35 mM NaHCO 3 ; 15 mM Na 2 CO 3 , pH 9.6) overnight at 41C. After blocking with 5% (w/v) fat-free milk/PBS-Tween for 1 h at room temperature, serum was serially diluted and incubated on the plates overnight at 41C. For detection, horseradish peroxidase-conjugated sheep anti-mouse Ig F(ab 0 ) 2 (Amersham, UK; 1:2000) was added for 1 h at room temperature. Plates were developed with tetramethylbenzidine dihydrochloride and absorbance was measured at 450 nm.
In some experiments, sera were preabsorbed onto plates coated with cell lysates from Adv0-infected HEK 293 cells, before transfer onto either plates coated with cell lysates from AdvsFlt-1-infected HEK 293 cells or with recombinant human sFlt-1, before detection as described above.
Proliferation assay
Inguinal lymph nodes were aseptically removed from AdvsFlt-, Adv0-and untreated arthritic mice 13 days after disease onset. Mononuclear cells (2 Â 10 5 cells) were cultured in 200 ml RPMI 1640 supplemented with 10% heat-inactivated FCS, penicillin and streptomycin (100 U/ml), L-glutamine (25 mM) and 2-mercaptoethanol (50 mM) in 30 mm 2 flat-bottomed plates. These cells were stimulated with denatured bovine collagen (50 mg/ml), UV-inactivated AdvsFlt-1 or Adv0 at 10 6 plaque-forming units (PFU), for antigenic recognition, and with PHA (2 mg/ml) for mitogenic stimulation. The cultures were incubated for 96 h at 371C in 5% CO 2 with 1 mCi/well of 3 H-thymidine for the last 16 h, before harvesting onto glass fibre filter mats with a Skatron cell harvester. Cellular DNA synthesis was assessed as 3 H-thymidine incorporation by BetaPlate system (Pharmacia, UK). Results are expressed as arithmetic mean cpm7s.e.m. from triplicate wells.
Quantification of VEGF, PlGF, sFlt-1 and vWF expression by ELISA Tissue extracts prepared from liver, spleen and knee joints from AdvsFlt-1-and Adv0-treated arthritic mice were assayed for sFlt-1 by ELISA using total soluble VEGFR-1 (sFlt-1) ELISA kit (ReliaTech, Braunschweig, Germany) according to the manufacturers' instructions. The sensitivity of the sFlt-1 assay was 100 pg/ml. Similarly, tissue extracts prepared from ankle joints from AdvsFlt-1-and Adv0-treated arthritic mice were assayed for von Willebrand factor (vWF) by ELISA using Asserachrom vWF kit (Roche, Tokyo, Japan) and for murine VEGF and PlGF-2 using R&D Quantikine s kits (R&D systems, Oxford, UK), all according to the manufacturers' instructions. Levels of vWF were expressed as percentages, in which detection was compared to levels present in human plasma calibration standard arbitrarily assigned a value of 100%. Absorbance was measured at 450 nm. Protein concentrations were calculated using BCA reagents (Sigma Poole, Dorset, UK).
Histology
Hind paws were removed at the end of the experiment and fixed in 10% buffered formalin. Tissue was decalcified with 5.5% (w/v) EDTA prior to embedding in paraffin wax blocks, sections were cut and stained with haematoxylin and eosin according to standard procedure. 18 Microscopic examinations of the joints of the foot and ankle were conducted with subjective grading of inflammation for pannus formation, synovitis, bone and cartilage erosion. The grading was as follows: normal; mild (minimal synovitis, some cartilage loss, shrinkage in the size of cartilage chondrocytes with denucleation and bone erosions limited to discrete foci); moderate (more extensive synovial hyperplasia, destruction of large segments of the cartilage and considerable bone erosions caused by an invasive pannus front); severe (complete destruction of the joint architecture). All analyses were performed in a blinded fashion by an observer unaware of the clinical status of the animal or treatment received.
Statistical analysis
Results were expressed as mean7s.e.m. with analyses performed using Graphpad Prism 3.0 (Graph Pad Software, CA, USA). Data were analysed by two-way analysis of variance (ANOVA), or one-way ANOVA with Bonferroni's multiple comparison test. The w 2 -test for trend was used to compare histological changes after AdvsFlt-1 treatment over 13 days. P-values less than 0.05 were considered to be statistically significant. AdvsFlt-1 reduces clinical score and footpad swelling in a dose-dependent manner
To determine whether treatment of arthritic mice with AdvsFlt-1 suppressed the severity of CIA, adenoviruses were administered at a single viral load of 10 7 PFU i.v. on the day of disease onset. This was the effective adenoviral dose with other therapeutic agents, for example, TNF-R Fc and IL-10. Since the nature of the model was such that the onset of disease can be quite variable, and individual mice can start displaying symptoms of arthritis at different times after immunization, we normalized the data between individual mice and treatment groups, and calculated the relative change from day 1 (disease onset) for both clinical scores and paw swelling, as described previously. 8, 18 Over the course of the experiment, the increase in clinical scores and paw swelling following administration of AdvsFlt-1 were significantly suppressed when compared to mice receiving 10 7 PFU Adv0 or untreated controls (both Po0.001; Figure 2 ). For example, on day 6 in AdvsFlt-1-treated arthritic mice, clinical scores were 0.6770.45, versus 1.8370.19 for untreated animals, a reduction of 63%. Footpad swelling appeared more sensitive to AdvsFlt-1 administration. On day 6, the mean paw swelling was 0.0570.04 mm for AdvsFlt-1-treated arthritic mice versus 0.2370.04 mm for untreated animals, a reduction of 78%. Suppression of disease was seen until day 10, but was not significant beyond this time point.
Disease activity was not affected in Adv0-treated arthritic mice, as both clinical scores and paw swelling were no different to controls up until day 7 (115 and 100%, respectively). However, beyond this time point, Adv0 treatment actually exacerbated both clinical scores. Intravenous administration of AdvsFlt-1 inhibits both clinical score and paw swelling. Mice were immunized with bovine collagen II to induce arthritis. On the first day of disease, adenoviruses AdvsFlt-1 (n¼36; K) or Adv0 (n¼32; m) were injected into the tail vein at a dose of 10 7 PFU. A further group of mice were left untreated (n¼29; '). Changes in clinical scores (a) and paw swelling (b) were monitored daily for 13 days. Results are expressed as change from day 1 (mean7s.e.m.), and were analysed by two-way ANOVA: ***Po0.001 for untreated versus AdvsFlt-1 and Adv0 for both clinical score and paw swelling; $$$ Po0.001 for Adv0 versus AdvsFlt-1 for both clinical score and paw swelling. In a separate experiment, AdvsFlt-1 and Adv0 were injected into arthritic mice at increasing adenoviral doses ranging from 10 5 to 10 8 PFU. Dose-dependent suppression of both clinical scores (data not shown) and paw swelling was observed with AdvsFlt-1. Doses of 10 5 and 10 6 PFU AdvsFlt-1 were ineffective, with optimal inhibition achieved with 10 7 PFU. A bell-shaped curve was clearly evident, since the higher dose of AdvsFlt-1 (10 8 PFU) showed no significant suppressive activity (Figure 3 ).
AdvsFlt-1 does not reduce mitogenic and antigenic proliferative responses in vitro
To determine whether the reduction in disease severity was due to an immunosuppressive effect of AdvsFlt-1, mononuclear cells isolated from AdvsFlt-1-and Adv0-infected mice, or untreated mice were stimulated with PHA and collagen II as an index of mitogenic and antigenic stimulation, respectively. The levels of 3 H-thymidine incorporation in response to PHA stimulation were all comparable: untreated mice 14 0107 2385 cpm, Adv0 treatment 14 41071732 cpm, AdvsFlt-1 treatment 17 57071367 cpm (P40.05 for AdvsFlt-1-treated versus either untreated or Adv0-treated by one-way ANOVA). Subsequently, data were normalized to the PHA response for each treatment group.
There was no significant difference in the rate of mononuclear cell proliferation in response to collagen II between untreated (922971780 cpm) and Adv0-treated mice (12 52771834 cpm). Although in AdvsFlt-1-treated mice proliferation to collagen was increased relative to PHA treatment (27 32972666 cpm), the differences between the groups were not statistically significant (P40.05 for AdvsFlt-1-treated versus either untreated or Adv0-treated by one-way ANOVA; Figure 4) . Similarly, the mononuclear cell responses to UV-inactivated AdvsFlt-1 or Adv0 did not exceed those elicited by PHA or collagen II stimulation in any group. Responses within the groups to the different exogenously added adenoviruses were also similar: in the untreated mice 22777902 cpm (response to exogenous Adv0) and 25437541 cpm (AdvsFlt-1), in Adv0-treated mice 45667423 cpm (Adv0) and 49067364 cpm (AdvsFlt-1), In order to assess expression of AdvsFlt-1 in vivo, tissue extracts were obtained from spleen, liver, synovium and lymph nodes from arthritic mice infected with AdvsFlt-1 and Adv0, or from untreated controls, 13 days after arthritis onset, and were blotted with anti-sFlt-1 antibody. However, when compared to control AdvsFlt-1-infected HEK 293 cells, no band corresponding to human sFlt-1 was obtained in any of the tissue samples at B100 kDa from AdvsFlt-1-infected mice (data not shown).
To further study the kinetics of sFlt-1 expression, liver and synovial tissue, extracts were prepared from arthritic mice 24 and 72 h after AdvsFlt-1 infection and were compared with liver extracts from naïve animals infected with AdvsFlt-1 or Adv0. Bands corresponding to sFlt-1 were obtained in liver extracts from arthritic mice 24 h, but not 72 h, after AdvsFlt-1 infection ( Figure 5 ). This band was absent in liver extracts from Adv0-infected arthritic mice (not shown) and all synovium extracts regardless of the time and type of viral infection. Liver extracts from naïve mice infected for 72 h with AdvsFlt-1 showed expression of sFlt-1 comparable to those found in arthritic mice after 24 h infection.
A commercially available human ELISA kit was used to quantify sFlt-1 expression in lysates alongside serum samples taken in parallel. Appreciable levels of sFlt-1 were detected in serum and both liver and knee joint tissue lysates 24 h after AdvsFlt-1 administration (Table  1) . However, these protein levels were not maintained, as more than 50% were lost in the lysates after 72 h, and sFlt-1 levels were totally undetectable in serum at this time point. Transgene expression appears to reach a steady state in both liver and synovium, as it remains at these levels in the liver and synovium for the rest of the experiment until day 13.
Production of anti-AdvsFlt-1 antibodies indicates that AdvsFlt-1 is immunogenic in vivo
Since the kinetics of sFlt-1 expression were shown to be transient following i.v. administration of AdvsFlt-1, we investigated the possibility that antibodies which specifically target AdvsFlt-1 were present. Microtitre plates were coated with cell lysates from Adv0-and AdvsFlt-1-infected HEK 293 cells. These plates were then incubated with serially diluted sera, obtained at the end of the experiment (day 13) from arthritic mice infected with AdvsFlt-1, Adv0 or from untreated controls. No anti-sFlt-1 or anti-adenoviral antibodies were detected in untreated mice, as demonstrated by lack of binding of serum samples to AdvsFlt-1-coated plates. Interestingly, sera from both Adv0-and AdvsFlt-1-infected arthritic mice elicited very similar responses, in that there was an increase in absorbance with increasing serum concentrations, suggesting the presence of specific antiadenovirus antibodies (not shown).
Preabsorption on Adv0-coated plates before incubation on AdvsFlt-1 plates was therefore used to separate antibodies against sFlt-1 and those against the adenoviruses, Adv0 and AdvsFlt-1, as these themselves only differ from each other by the gene product. Subsequently, preabsorbed sera were serially diluted on plates coated with cell lysates from AdvsFlt-1-infected HEK 293 cells. Sera from mice infected with either Adv0 or AdvsFlt-1 gave almost identical absorbance curves on AdvsFlt-1-coated plates, giving 50% absorbance (OD 50 ) at a dilution of 1/128, whereas sera from untreated controls failed to bind (Figure 6a) .
In contrast, sera from arthritic mice infected with AdvsFlt-1 showed significant binding to recombinant human sFlt-1 (OD 50 ¼1/256; Figure 6b ) absorbance curves, which was not seen with sera from Adv0-treated or untreated mice, indicating the presence of anti-human sFlt-1 antibodies within this group.
AdvsFlt-1 reduces synovial inflammation and bone destruction in CIA
Histological analysis using haematoxylin and eosin was performed on paws taken from untreated, Adv0-and AdvsFlt-1-treated arthritic mice 13 days after disease onset, and sections were graded in a blinded manner. Arthritic mice were injected with AdvsFlt-1 (10 7 PFU) intravenously into the tail vein. At designated intervals after adenoviral administration, serum was obtained, and lysates from liver and knee joints were prepared. Soluble VEGF receptor 1 (sFlt-1) levels were measured by ELISA, and expressed normalized per mg protein.
ND¼not detected (o100 pg/ml).
Adenoviral delivery of sFlt-1 inhibits murine arthritis AO Afuwape et al
The percentage of animals exhibiting normal, mild, moderate or severe changes in bone/cartilage and synovitis was calculated.
Sections from untreated and Adv0-infected arthritic mice revealed significant pannus formation, as indicated by the thickening of synovial layer, accompanied by extensive leucocyte infiltration within the joint space and synovial lining. Erosions of the articular cartilage and bone described as moderate (synovial hyperplasia, destruction of large segments of the cartilage and considerable bone erosions caused by an invasive pannus front) were observed in 37 and 44% of joints taken from untreated and Adv0-infected mice, respectively, whereas complete destruction of the joint architecture was observed in 35 and 25% of these sections. In contrast, sections from mice, which had received AdvsFlt-1, showed minimal synovitis and leucocyte infiltration and were devoid of severe bone or cartilage erosion (Figure 7 ; Po0.001 versus untreated and Adv0-treated by w 2 -test for trend). Overall, 68% of these sections were considered to have normal cartilage and bone architecture at joint interfaces. An example of the histological appearance of proximal phalanx joints following different treatments is shown in Figure 7b .
Analysis of individual joints showed that AdvsFlt-1-induced protection was more apparent at the tarsal and metatarsal joints. For example, 10 out of 12 (83%) examined tarsal sections from AdvsFlt-1-treated mice Figure 6 Detection of specific antibodies to both adenovirus and transgene after AdvsFlt-1 and Adv0 administration. Serum was obtained from arthritic mice 13 days after adenoviral administration, and was serially diluted and incubated on ELISA plates precoated with (a) lysates from AdvsFlt-1-infected HEK 293 cells and (b) recombinant human sFlt-1, following Adv0 preabsorption in both cases. Specific murine immunoglobulins to either AdvsFlt-1 or recombinant human sFlt-1 were detected using 1/1000 sheep anti-mouse Ig F(ab 0 ) 2 , and the absorbance measured at 450 nm. Results are plotted as OD values versus Àlog of the serum dilution. Insets show absorbance measured at 450 nm at (a) 1/128 serum dilution, which is equivalent to 50% absorbance on lysates from AdvsFlt-1-infected HEK 293 cells, (b) 1/256 serum dilution, which is equivalent to 50% absorbance on recombinant human sFlt-1. Adenoviral delivery of sFlt-1 inhibits murine arthritis AO Afuwape et al exhibited no destruction of bone/cartilage. This contrasted with only 1 out of 10 (10%) normal paws from untreated animals (Po0.001 versus K1-5) and zero out of nine (0%) paws from Adv0-treated animals (Po0.001). A similar pattern was observed for first metatarsal joints. For proximal and distal phalanx joints, the differences were less apparent, but nonetheless statistically significant.
Vascularity is reduced in the joints of AdvsFlt-1-treated arthritic mice
As an index of joint vascularity, vWF was assessed in lysates prepared from ankle joints of arthritic mice 4-6 days after adenoviral administration, and compared to mice that were immunized with collagen II but were yet to show any signs of arthritis. Levels of vWF levels were expressed as percentages in which detection was compared to levels present in human plasma calibration standard arbitrarily assigned a value of 100%. Ankle joint lysates obtained from untreated arthritic mice showed significantly elevated levels of total vWF when compared with those taken from prearthritic mice (18.3571.83 versus 5.8070.47%; Po0.001 by one-way ANOVA; Figure  8a ). Blood vessel density, calculated by expressing vWF as a function of protein levels, also indicated an increase in untreated samples relative to healthy animals (17.1370.85% per mg protein versus 13.4070.79% per mg protein; Po0.01 by one-way ANOVA; Figure 8b ). The effect of adenoviral treatment was assessed relative to the increase in vascular density from healthy to arthritic mice (3.73% per mg protein). AdvsFlt-1 treatment significantly inhibited the increase in vascular density associated with arthritis (reduction 97723%; Po0.05 versus untreated mice by one-way ANOVA; Figure 8c ), whereas vascular density in Adv0-treated mice was not significantly suppressed (reduction 39730%; P40.05 versus untreated mice).
VEGF but not PlGF, is expressed in the joints of arthritic mice and is suppressed by AdvsFlt-1 treatment
It is possible that PlGF, another ligand of membranebound Flt-1, could also act as a mediator of angiogenesis, and that AdvsFlt-1 could block the actions of this growth factor in addition to those of VEGF. Ankle lysates from arthritic mice taken 6-8 days after disease onset were therefore assayed for both VEGF and PlGF and compared to lysates from prearthritic mice ( Table 2) . No detectable levels of PlGF were found in either prearthritic or arthritic samples, whereas VEGF was found to be elevated following arthritis onset (untreated arthritic versus prearthritic Po0.01). Furthermore, treatment with AdvsFlt-1 significantly reduced the levels of VEGF when compared to those untreated or treated with Adv0 (Po0.05).
Discussion
Formation of new blood vessels has been suggested to be of importance in the pathogenesis of RA, in that the expansion of synovial tissue necessitates a compensatory increase in the number and density of synovial blood vessels. The arthritic synovium is in fact a very hypoxic environment, and hypoxia is a potent signal for the generation of new blood vessels, predominantly through the induction of VEGF, a hypoxia-sensitive angiogenic factor. Indeed, it is now generally accepted that neovascularization is central to maintaining and promoting RA, and that a potential method of attenuating development of the pannus is to interfere with its blood Figure 8 Measurement of vWF as an index of vascularity: reduction in AdvsFlt-1-treated mice. After immunization with bovine collagen II, mice were either left untreated (n¼7) or injected with 10 7 PFU of either Adv0 (n¼6) or AdvsFlt-1 (n¼8) on the day of disease onset. A further group of animals were killed after immunization with collagen, but prior to onset of disease (n¼8). After 4-6 days, ankle joints were removed post mortem from prearthritic and untreated arthritic mice, tissue lysates were prepared, and vWF levels were measured by ELISA and expressed as % relative to a human plasma calibration standard arbitrarily assigned a value of 100%. Comparison of (a) total vWF levels (b) vWF levels normalized per mg protein, in joint lysates from prearthritic and untreated arthritic mice. (c) Comparison of vWF levels in untreated arthritic mice, or animals injected with either Adv0 or AdvsFlt-1. Values are expressed as relative to the increase in vascularity in untreated arthritic mice. All data are mean7s.e.m.; *Po0.05, **Po0.01, ***Po0.001 versus untreated arthritic animals by one-way ANOVA with Bonferroni's multiple comparison test.
Adenoviral delivery of sFlt-1 inhibits murine arthritis AO Afuwape et al supply. The murine CIA model resembles the synovitis, pannus formation and bone and cartilage destruction observed in RA, and was successfully used to demonstrate the role of TNFa in arthritis and to develop antiTNFa therapy. 19, 20 We have previously reported that synovial cells isolated from arthritic mice produce significantly more VEGF in vitro than cells from healthy controls, with the amount of VEGF released correlating with the severity of arthritis and with the extent of paw swelling. 8 More recently, we showed that onset of CIA is associated with a reduction in synovial oxygen tension, which is likely to upregulate VEGF expression 21 and perhaps other cytokines. The aim of the present study was to examine whether adenovirally-delivered VEGF receptor can modulate the severity of CIA. We observed that a single injection of adenovirus overexpressing soluble VEGF receptor sFlt-1 successfully suppressed both clinical scores (up to day 10 after disease onset) and paw swelling, with the latter appearing to be more susceptible to VEGF blockade. Furthermore, histological assessment of the paws taken from AdvsFlt-1-infected arthritic mice revealed a high percentage of joints with preserved structure and little or no bone and cartilage erosion. Thus, gene delivery of sFlt-1 to sequester VEGF, and/or dimerize with membrane-bound VEGF-R1 to block VEGF, reduces the severity of CIA, confirming and extending our previous findings using PEG-linked recombinant sFlt-18, and supports the hypothesis that inhibition VEGF expression in arthritis could be of therapeutic benefit.
Several broadly acting angiogenesis inhibitors, such as AGM-1470 (TNP-470), have been described to reduce disease in rodent models. [22] [23] [24] [25] [26] Moreover, retrovirally delivered angiostatin also reduced pannus formation and neovascularization. 27 Other studies have reported that endostatin, a 20 kDa fragment of collagen XVIII, can also reduce disease. Intrasynovial injection of human recombinant endostatin reduced both the volume of grafted synovium and the number of vessels in SCID mice engrafted with human RA synovium. 28 Similarly, endostatin-expressing lentivirus injected directly into the joints of human TNF-transgenic mice before the onset of disease reduced synovial blood vessel density and arthritis severity. 29 Direct blockade of VEGF in CIA has also been achieved using polyclonal anti-VEGF antibodies raised in rabbits. 30, 31 Finally, K1-5 (protease-activated kringles 1-5), an angiogenesis inhibitor related to angiostatin directly acting on endothelium, significantly reduced both the paw swelling and the clinical score in CIA. The efficacy of this treatment was reflected in a reduction in joint inflammation and destruction, as assessed histologically. 18 Although angiostatin, endostatin, anti-VEGF antibody, recombinant sFlt-1 and K1-5 have all been suggested to reduce CIA through inhibition of neovascularization, this has been difficult to prove. Antimurine VEGF antibody was only able to reduce disease incidence, severity and the level of vWF expression, as an index of vascularity, if injected before disease onset. 31 The association of vascularity with VEGF content in CIA observed in the study by Lu et al was of interest, in that tissue extracts from arthritic mice were shown to have high levels of biologically active VEGF and vWF that together peaked 4 days after disease onset. 31 To determine the mechanism of action of AdvsFlt-1 in CIA, we measured VEGF, PlGF and vWF in the ankle joints of arthritic and prearthritic (without disease) mice and demonstrated that there is an increase in levels of both VEGF and vWF, both in terms of absolute values and when normalized to protein.
Carmeliet et al reported that blockade of Flt-1, but not Flk-1, receptor was effective in the suppression of arthritic joint destruction and suggested that PlGF could be a possible mediator of neovascularization in arthritis. 32 However, we were unable to measure detectable levels of this growth factor in our model of arthritis, although we were able to demonstrate an increase in VEGF expression in untreated arthritic mice supporting earlier data from our own and other laboratories. Furthermore, we found that AdvsFlt-1 was not only effective in suppressing both clinical scores and paw swelling, but also significantly reduced both VEGF and vWF levels in ankle lysates from AdvsFlt-1-treated mice when compared to untreated controls. These data suggested a role for VEGF-mediated neovascularization at an early stage of arthritis development. We cannot discount a role for PlGF in the mechanism of pannus formation in the arthritic joint, but feel that due to its undetectable levels the actions of PlGF would be secondary to those of VEGF. Interestingly, anti-human VEGF antibody was able to prevent and suppress the severity and incidence of arthritis and paw swelling, with treatment both at the time of immunization and at disease onset being effective. 30 However, the suppression in clinical scores and paw swelling following arthritis onset was not as great as that achieved during the preventative regime (antibody administered before disease onset); so early intervention appears to be the common finding among all the studies.
The advantage of using adenoviruses for gene therapy compared with retroviruses is the ability to induce high and prolonged levels of protein expression in a wide range of cell types, with expression not being restricted to cells undergoing replication. A study using adenovirus encoding for TNF receptor p55 (AdvTNFR) in CIA produced a similar duration of suppression to that observed in the current study, lasting until day 10 after disease onset. 9 However, a rebound affect occurred beyond this point, and significant deterioration was observed in AdvTNFR-treated mice, which was not seen with arthritic mice receiving repeated injections of In our study, we observed that 10 days after onset of arthritis, the effect of AdvsFlt-1 was considerably less pronounced, and Adv0-treated mice actually showed exacerbation of disease. The probable reason for such discrepancies seen in the duration of suppression could be the nature of the gene products, since both CTLA-4Ig and IL-10 possess potential immunosuppressive properties and were of murine origin. In contrast, AdvsFlt-1 and AdvTNFR encode for human soluble receptors that sequester VEGF and TNFa and have no direct immunosuppressive effect. This is supported by the observations that antigenic and mitogenic proliferative responses were not altered with either AdvsFlt-1 or AdvTNFR treatment when compared to untreated controls (our data and Quattrocchi et al ). Specific antibody IgG responses to collagen II, both for total IgG and IgG1:IgG2a ratio, were unaffected in arthritic mice infected with AdvTNFR9. However, both AdvCTLA4Ig and IL-10 showed evidence of inhibiting immune responses, such as reducing proliferation in response to collagen II and anti-CD3 stimulation, and decreasing levels of collagen II IgG antibodies. 10, 35, 36 Another explanation for the reduced efficacy of AdvsFlt-1 at later times following arthritis onset is that adenoviruses, particularly of those with E1a and E3 deletions, such as those used in our study, are prone to be immunogenic, with the subsequent host antiadenoviral response drastically restricting transgene expression. 37, 38 There appears to be a fine balance between the need to deliver as much of the transgene sFlt-1 into the model as possible without using a high enough adenoviral dose to trigger the host defence mechanism. This was suggested by the ineffective action of 10 8 PFU despite the dosedependent increase in disease suppression by AdvsFlt-1 from 10 5 PFU up until the optimum dose of 10 7 PFU. Furthermore, using ELISA and Western blot analysis, we found that expression of sFlt-1 was very transient and diminished from an initial peak 24 h after injection to just above background levels at 72 h. Liver extracts from naïve mice infected with AdvsFlt-1 showed significant sFlt-1 expression at 72 h, indicating that lack of disease in these mice may allow for the persistence of the adenovirus. Importantly, sFlt-1 expression within synovial tissue and liver extracts in arthritic animals confirmed that AdvsFlt-1 reached both systemic and effector sites. Measurement of antiadenovirus antibodies showed that injections of both Adv0 and AdvsFlt-1 elicited identical responses that were not altered with Adv0 preabsorption. However, an anti-human sFlt-1 response was observed in sera obtained from AdvsFlt-1-but not Adv0-infected mice. Therefore, there appears to be a response to both the adenoviruses and the transgene, sFlt-1, which restricts the efficacy of the AdvsFlt-1. This is not surprising, since it has been reported that AdvIL-4 increased antiadenovirus responses after i.v. administration. 39 Given the apparent host defence mechanism against AdvsFlt-1, the levels of expression in the liver were quite high, being approximately 100-fold greater than those found with AdvIL-10 and AdvIL-4 in CIA 34, 36 and adenovirus encoding for murine IL-10 in a colitis model 40 at the same time interval after i.v. injection. In summary, we were able to suppress clinical scores, paw swelling and most importantly joint destruction with administration of AdvsFlt-1. Expression was demonstrated in both systemic and effector regions, but were transient due to antibody responses targeting both the adenovirus and human transgene. We were able to verify that this treatment reduced blood vessel formation. These data suggest that approaches targeting VEGF and neovascularization could be an exciting future therapeutic possibility for human RA.
